Ariosa's non invasive prenatal screening (NIPS) test, the Harmony Prenatal Test, is one of the most widely studied tests utilized in prenatal screening
BioReference Laboratories Acquires U.S. Ariosa Centralized Laboratory Prenatal Testing Business. (Credit: Ahmad Ardity from Pixabay)
BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced the acquisition of the U.S. Ariosa centralized laboratory prenatal testing business from Roche.
Ariosa’s non invasive prenatal screening (NIPS) test, the Harmony Prenatal Test, is one of the most widely studied tests utilized in prenatal screening. The test has been performed in over 1.5 million patients. GenPath, BioReference’s specialty health division, currently offers, ClariTest™ Core, which utilizes the same core technology as the Harmony Prenatal Test. The acquisition of Ariosa will complement this current NIPS offering.
“Throughout BioReference’s 40 year legacy of diagnostic testing, women’s health has been at the forefront of our focus,” said Jon R. Cohen, M.D., Executive Chairman of BioReference Laboratories. “Last year, there were about six million pregnancies in the U.S., and prenatal screening for Down syndrome has become common practice. Acquiring the U.S. Ariosa centralized laboratory prenatal testing business allows us to expand our NIPS offerings and further underscores our commitment to prenatal screening, allowing BioReference and GenPath to advance high quality and accessible testing that positively impacts the medical care and outcomes of patients and their families.”
BioReference Laboratories, Inc., is one of the largest full service specialty laboratories in the United States that gives healthcare providers and patients the power to make confident healthcare decisions. With a focus on genetics, oncology, urology and women’s health, BioReference offers comprehensive test solutions and unparalleled expertise based on a 40 year legacy of proven science.
OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies.
Source: Company Press Release